(S)-3-amino-1,2,3,4-tetrahydroquinoline-6-carbonitrile | 851758-85-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (S)-3-amino-1,2,3,4-tetrahydroquinoline-6-carbonitrile
• 英文别名: (3S)-3-amino-1,2,3,4-tetrahydroquinoline-6-carbonitrile
• CAS: 851758-85-5
• 化学式: C₁₀H₁₁N₃
• 分子量: 173.217
• InChiKey: KPBTYGLETKFPDD-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-3-amino-1,2,3,4-tetrahydroquinoline-6-carbonitrile 在 三乙基硅烷 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 N-[(S)-6-Cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-benzenesulfonamide
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors

  摘要：

  Tetrahydroquinoline-based small molecule inhibitors of farnesyltransferase (FT) have been identified. Lead compounds were shown to have nanomolar to sub-nanomolar activity in biochemical assays with excellent potency in a Ras-mutated cellular reversion assay. BMS-316810 (9e), a 0.7 nM FT inhibitor, was orally-active in a nude mouse tumor allograft efficacy study. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.02.004
• 作为产物：
  描述：

  (6-Bromo-1,2,3,4-tetrahydro-3-quinolinyl)carbamic acid, 1,1-dimethylethyl ester 在 四(三苯基膦)钯 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 (S)-3-amino-1,2,3,4-tetrahydroquinoline-6-carbonitrile
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors

  摘要：

  Tetrahydroquinoline-based small molecule inhibitors of farnesyltransferase (FT) have been identified. Lead compounds were shown to have nanomolar to sub-nanomolar activity in biochemical assays with excellent potency in a Ras-mutated cellular reversion assay. BMS-316810 (9e), a 0.7 nM FT inhibitor, was orally-active in a nude mouse tumor allograft efficacy study. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.02.004

文献信息

• Bicyclic heterocycles as cannabinoid receptor modulators
  申请人：Sun Chongqing

  公开号：US20060160850A1

  公开（公告）日：2006-07-20

  The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R 1 , R 2 , R 3 , n, and Z are described herein.

  本申请描述了符合I式的化合物，包括至少一种符合I式的化合物的药物组合物，以及可选地包含一种或多种额外治疗剂的药物组合物和使用符合I式的化合物进行治疗的方法，无论是单独使用还是与一种或多种额外治疗剂结合使用。这些化合物具有一般的I式： 包括所有的前药、药用可接受的盐和立体异构体，R1、R2、R3、n和Z在此处描述。
• Tetrahydroquinoline derivatives as cannabinoid receptor modulators
  申请人：Sun Chongqing

  公开号：US20050014786A1

  公开（公告）日：2005-01-20

  The invention provides for compounds of formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.

  该发明提供了式I的化合物，其中取代基如本文所述。进一步提供了使用这些化合物治疗进食障碍、代谢障碍、肥胖症、认知障碍、神经系统障碍、疼痛障碍、炎症障碍、促进戒烟和治疗其他精神障碍的方法。还提供了含有这些化合物的制药组合物和该发明化合物与其他治疗剂的制药组合。
• TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS
  申请人：Sun Chongqing

  公开号：US20080194625A1

  公开（公告）日：2008-08-14

  The invention provides for compounds of formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.

  本发明提供了式I的化合物，其中取代基如本文所述。还提供了使用这些化合物治疗进食障碍、代谢障碍、肥胖症、认知障碍、神经系统疾病、疼痛障碍、炎症障碍、促进戒烟和治疗其他精神障碍的方法。还提供了含有这些化合物的药物组合物以及本发明化合物与其他治疗剂的药物组合物。
• TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS
  申请人：Sun Chongqing

  公开号：US20080200459A1

  公开（公告）日：2008-08-21

  The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R 1 , R 2 , R 3 , n, and Z are described herein.

  本申请描述了具有I式的化合物，其中包括至少一种I式化合物和可选的一种或多种额外治疗剂的制药组合物，以及使用I式化合物进行单独治疗和与一种或多种额外治疗剂组合治疗的方法。这些化合物的一般式I如下，包括所有的前药、药学可接受的盐和立体异构体，其中R1、R2、R3、n和Z的描述如下：
• Tetrahydroquinoline cannabinoid receptor modulators
  申请人：Bristol-Myers Squibb Company

  公开号：US07709647B2

  公开（公告）日：2010-05-04

  The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, n, and Z are described herein.

  本申请描述了符合公式I的化合物，包括至少一种符合公式I的化合物和可选的一种或多种其他治疗剂量的制药组合物，以及使用符合公式I的化合物单独或与一种或多种其他治疗剂量联合使用的治疗方法。这些化合物的一般公式I包括所有的前药、药学上可接受的盐和立体异构体，其中R1、R2、R3、n和Z的描述在此处。